Gene · 4507
Papers2,281
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,281
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Peri-Implant Gingival Undifferentiated SWI/SNF Complex-Deficient Tumor with Molecularly Confirmed Biallelic SMARCA4 Inactivation: Diagnostic Pitfalls and Genomic Characterization. | Diagnostics (Basel) | 2026 | 42279597 | PubTator, text mining | PubMed |
| Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors. | JCO Precis Oncol | 2026 | 42258781 | PubTator, text mining | PubMed |
| Clinicopathological significance of methylthioadenosine phosphorylase (MTAP) expression loss in hepatobiliary tumors. | Hum Pathol | 2026 | 42242395 | PubTator, text mining | PubMed |
| Convergence of KRAS Mutations and MTAP Loss in Pancreatic Cancer: Genomic Landscape and Clinical Implications. | Clin Cancer Res | 2026 | 42240448 | PubTator, text mining | PubMed |
| Febuxostat enhances the anti-tumor efficacy of 2-fluoroadenine and 5'-methylthioadenosine in MTAP-deleted cancer. | bioRxiv | 2026 | 42239469 | PubTator, text mining | PubMed |
| The First Report of BRAF V600E Mutation in Paratesticular Mesothelioma. | Int J Surg Pathol | 2026 | 42237856 | PubTator, text mining | PubMed |
| LKB1 inactivation elicits an NNMT-mediated methyl sink and confers dependence on PRMT5 in lung cancer. | Cell Rep | 2026 | 42234565 | PubTator, text mining | PubMed |
| Clinicopathologic, molecular, and treatment features of metastatic and distantly recurrent extramammary Paget disease: Mayo clinic experience. | Oncologist | 2026 | 42231129 | PubTator, text mining | PubMed |
| Localised malignant mesothelioma presenting as an esophageal mass: An unusual manifestation. | Radiol Case Rep | 2026 | 42211276 | PubTator, text mining | PubMed |
| Novel Synthetic Lethal Therapeutic Strategies in Precision Oncology. | Am Soc Clin Oncol Educ Book | 2026 | 42207998 | PubTator, text mining | PubMed |
| Sequential multimodal management for recurrent pulmonary NUT carcinoma: a case report. | Front Oncol | 2026 | 42205759 | PubTator, text mining | PubMed |
| MTAP Deficiency as a Metabolic Vulnerability in Cancer: Implications for Synthetic Lethal Therapy. | Cancer Sci | 2026 | 42198893 | PubTator, text mining | PubMed |
| A High-Fidelity Patient-Derived Organoid Platform Recapitulates the Dynamic Metabolic Landscape of Cisplatin Tolerance in Mesothelioma. | Cancers (Basel) | 2026 | 42192862 | PubTator, text mining | PubMed |
| Structure-based discovery of a highly potent, selective, and brain-penetrant MTA-cooperative PRMT5 synthetic lethal inhibitor for the treatment of glioblastoma. | Eur J Med Chem | 2026 | 42190431 | PubTator, text mining | PubMed |
| A high-penetrance intergenic variant at 9p21 confers melanoma susceptibility. | Res Sq | 2026 | 42183343 | PubTator, text mining | PubMed |
| Clinicogenomic Landscape of MTAP-Deleted Thoracic Malignancies Across US and Japanese Nationwide Cohorts: Impact of Concurrent CDKN2A Alterations and Driver Mutations. | JCO Precis Oncol | 2026 | 42172559 | PubTator, text mining | PubMed |
| Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical Evaluation. | J Med Chem | 2026 | 42172174 | PubTator, text mining | PubMed |
| Mesothelioma in situ-spectrum pleural lesions: Diagnostic challenges and longitudinal follow-up in a case series. | Pathol Res Pract | 2026 | 42166937 | PubTator, text mining | PubMed |
| Update on the Development of Targeting Arginine Methyltransferase PRMT5 in Cancer Research. | Curr Top Med Chem | 2026 | 42163734 | PubTator, text mining | PubMed |
| The Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions. | Diagn Cytopathol | 2026 | 42163521 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4507/papers?page=4